Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 3:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Opioid Induced Constipation Clear all
Completed Phase 3 Interventional

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

NCT01427270
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
170
States / cities
Alabaster, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

NCT01655771
View directory record Official record
Conditions
Constipation
Interventions
TD-1211 Dose 1, TD-1211 Dose 2
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 2 Interventional Results available

Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

NCT01004393
View directory record Official record
Conditions
Neoplasms, Constipation, Opioid-Related Disorders
Interventions
Methylnaltrexone bromide
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 2 Interventional

Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)

NCT01983306
View directory record Official record
Conditions
Constipation
Interventions
SP-333 1 mg, SP-333 3 mg, SP-333 6 mg, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
42
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 3 Interventional Results available

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

NCT01323790
View directory record Official record
Conditions
Opioid-Induced Constipation (OIC)
Interventions
NKTR-118, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
68
States / cities
Mobile, Alabama • Pell City, Alabama • Mesa, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Jul 21, 2026, 3:40 PM EDT
Not listed Phase 2Phase 3 Interventional

Naloxegol and Opioid-induced Constipation

NCT03316859
View directory record Official record
Conditions
Constipation, Constipation Drug Induced
Interventions
Naloxegol 25 MG, Placebo pill
Drug · Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain

NCT00547586
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728), placebo
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Mobile, Alabama • Litchfield Park, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

NCT01298219
View directory record Official record
Conditions
Opioid-induced Bowel Dysfunction
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
115
States / cities
Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Jul 21, 2026, 3:40 PM EDT
Terminated Phase 4 Interventional Results available

Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)

NCT02839889
View directory record Official record
Conditions
Cancer, Constipation, Pain
Interventions
Naloxegol, Placebo
Drug
Lead sponsor
Hospice of Henderson County, Inc.
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
New York, New York • Flat Rock, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

NCT01965158
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

NCT01040637
View directory record Official record
Conditions
Healthy, Opioid-induced Constipation
Interventions
TD-1211, Placebo
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Pasadena, California • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 3:40 PM EDT
Withdrawn Phase 4 Interventional

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

NCT00858754
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
methylnaltrexone, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Laguna Hills, California • Lancaster, California • Flat Rock, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-1211 IV/Oral Mass Balance Study

NCT01702194
View directory record Official record
Conditions
OIC
Interventions
TD-1211 IV [C14], TD-1211 PO [C14]
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 3:40 PM EDT
Terminated Phase 3 Interventional Results available

Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain

NCT01384292
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
NKTR-118, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
81
States / cities
Huntsville, Alabama • Casa Grande, Arizona • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

NCT00529087
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728), placebo
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Mobile, Alabama • Sun City, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)

NCT00600119
View directory record Official record
Conditions
Opioid Induced Constipation (OIC)
Interventions
placebo, NKTR-118
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Huntsville, Alabama • Pinson, Alabama • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 4 Interventional Results available

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

NCT03060512
View directory record Official record
Conditions
Opioid Induced Constipation
Interventions
Polyethylene Glycol 3350, Movantik
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
53
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone

NCT00620061
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone 24
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
120
States / cities
Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 95 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain

NCT01122030
View directory record Official record
Conditions
Opioid Induced Bowel Dysfunction
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 2 Interventional

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

NCT00135577
View directory record Official record
Conditions
Cancer, Bowel Dysfunction
Interventions
alvimopan, placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
14
States / cities
Duarte, California • Fountain Valley, California • La Verne, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Jul 21, 2026, 3:40 PM EDT
Not listed Phase 3 Interventional

Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit

NCT01050595
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Methylnaltrexone Bromide, Placebo-Normal Saline
Drug
Lead sponsor
St. John Health System, Michigan
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

NCT00804141
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
94
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 2 Interventional

A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)

NCT01401985
View directory record Official record
Conditions
Opioid Induced Constipation
Interventions
TD-1211, Placebo
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 3:40 PM EDT
Completed Phase 3 Interventional

Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

NCT00259922
View directory record Official record
Conditions
Bowel Dysfunction, Constipation
Interventions
Placebo, Alvimopan, Alviompan
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
119
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 104 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Jul 21, 2026, 3:40 PM EDT